Search results for "Prognosis."

showing 10 items of 2044 documents

Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable res…

2021

Programa para el Tratamiento de Hemopatias Malignas (PETHEMA) Group (Spanish Society of Hematology, SEHH).

OncologyMalep13)/TCF3-PBX1Neoplasm ResidualOncogene Proteins FusionCytogenetic alterationsmedicine.medical_treatmentDiseaseTranslocation Genetichemic and lymphatic diseasesAntineoplastic Combined Chemotherapy Protocolst(1;19)(q23;p13)/TCF3-PBX1Cumulative incidenceCitogenètica humanaNeoplasm MetastasisLeucèmia limfoblàstica - TractamentHuman cytogeneticsLeukemiaAcute lymphoblastic leukaemiaRemission InductionLeucèmiaDisease ManagementHematologyMiddle AgedPrognosisHaematopoiesismedicine.anatomical_structureTreatment OutcomeChromosomes Human Pair 1TCF3:Other subheadings::Other subheadings::/therapy [Other subheadings]FemaleStem cell:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Lymphoid::Precursor Cell Lymphoblastic Leukemia-Lymphoma::Precursor B-Cell Lymphoblastic Leukemia-Lymphoma [DISEASES]Adultmedicine.medical_specialtyPronòstic mèdicAdolescentQuimioteràpia combinadaYoung AdultInternal medicinePrecursor B-Cell Lymphoblastic Leukemia-LymphomamedicineAdultsHumansB cell19)(q23Neoplasm Staging:neoplasias::neoplasias por tipo histológico::leucemia::leucemia linfoide::leucemia-linfoma linfoblástico de células precursoras::leucemia-linfoma linfoblástico de células B precursoras [ENFERMEDADES]business.industryacute lymphoblastic leukaemia adults cytogenetic alterations prognosis t(1:Otros calificadores::Otros calificadores::/terapia [Otros calificadores]ImmunotherapyChromosome BandingTransplantationt(1Avaluació de resultats (Assistència sanitària)businessChromosomes Human Pair 19British journal of haematologyReferences
researchProduct

Flower lose, a cell fitness marker, predicts COVID‐19 prognosis

2021

Abstract Risk stratification of COVID‐19 patients is essential for pandemic management. Changes in the cell fitness marker, hFwe‐Lose, can precede the host immune response to infection, potentially making such a biomarker an earlier triage tool. Here, we evaluate whether hFwe‐Lose gene expression can outperform conventional methods in predicting outcomes (e.g., death and hospitalization) in COVID‐19 patients. We performed a post‐mortem examination of infected lung tissue in deceased COVID‐19 patients to determine hFwe‐Lose’s biological role in acute lung injury. We then performed an observational study (n = 283) to evaluate whether hFwe‐Lose expression (in nasopharyngeal samples) could accu…

OncologyMedicine (General)medicine.medical_specialtyFlowersDiseaseQH426-470Lung injurySeverity of Illness Indexcell fitnessArticleR5-920COVID‐19Internal medicineSeverity of illnessGeneticsmedicineHumansPandemicsRetrospective StudiesReceiver operating characteristicSARS-CoV-2business.industryCOVID-19Retrospective cohort studyArticlesTriageMicrobiology Virology & Host Pathogen InteractionflowerROC CurvebiomarkerMolecular MedicineBiomarker (medicine)Observational studyprognosisbusinessBiomarkersEMBO Molecular Medicine
researchProduct

Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experienc…

2020

Background Malignant germ cell tumors (GCTs) are a heterogeneous group of rare neoplasms in children. Optimal outcome is achieved with multimodal therapies for patients with both localized and advanced disease, especially after the introduction of platinum-based chemotherapy regimens. In this respect, data on salvage treatment for children with relapsed or platinum-refractory disease are still limited. Methods Retrospective analysis of data regarding patients affected by malignant GCTs with platinum-refractory or relapsed disease after first-line treatment according to AIEOP TCGM 2004 protocol was conducted. Results Twenty-one patients, 15 females and 6 males, were considered for the analys…

OncologyMelphalanMalemedicine.medical_treatmentDrug ResistanceSalvage therapyrelapsed tumorsDeoxycytidineCarboplatinchemistry.chemical_compound0302 clinical medicineNeoplasmsAntineoplastic Combined Chemotherapy Protocolsgerm cell tumorsChildEtoposideIfosfamideRemission InductionHematologyNeoplasms Germ Cell and EmbryonalPrognosisgerm cell tumors; high-dose chemotherapy; pediatric tumors; refractory tumors; relapsed tumors; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child Preschool; Cisplatin; Deoxycytidine; Drug Resistance Neoplasm; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Infant; Male; Neoplasm Recurrence Local; Neoplasms Germ Cell and Embryonal; Oxaliplatin; Paclitaxel; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Salvage Therapypediatric tumorsOxaliplatinSurvival RateLocalOncology030220 oncology & carcinogenesisChild PreschoolFemalerefractory tumorsmedicine.drugmedicine.medical_specialtyAdolescentPaclitaxelThioTEPA03 medical and health sciencesInternal medicinemedicineHumansIfosfamidePreschoolSurvival rateRetrospective StudiesSalvage TherapyChemotherapybusiness.industryInfantmedicine.diseaseGemcitabineCarboplatinNeoplasm RecurrencechemistryDrug Resistance NeoplasmPediatrics Perinatology and Child HealthSettore MED/20NeoplasmGerm Cell and EmbryonalGerm cell tumorsCisplatinNeoplasm Recurrence Localbusinesshigh-dose chemotherapy030215 immunologyFollow-Up StudiesPediatric bloodcancerREFERENCES
researchProduct

Prognostic Significance of Interferon-γ and Its Signaling Pathway in Early Breast Cancer Depends on the Molecular Subtypes

2020

Interferons are crucial for adaptive immunity and play an important role in the immune landscape of breast cancer. Using microarray-based gene expression analysis, we examined the subtype-specific prognostic significance of interferon-&gamma

OncologyMicroarrayReceptor ErbB-2animal diseasesKaplan-Meier Estimatelcsh:ChemistryMedicinelcsh:QH301-705.5Spectroscopymolecular subtypesHazard ratioGeneral MedicineinterferonMiddle AgedAcquired immune systemProgression-Free SurvivalComputer Science ApplicationsGene Expression Regulation NeoplasticReceptors EstrogenCohortFemaleReceptors ProgesteroneSignal Transductionmedicine.medical_specialtyBreast Neoplasmschemical and pharmacologic phenomenaDisease-Free SurvivalArticleCatalysisInorganic ChemistryInterferon-gammaBreast cancerImmune systembreast cancerInternal medicineBiomarkers TumorHumansPhysical and Theoretical ChemistryMolecular BiologyAgedNeoplasm Stagingbusiness.industryProportional hazards modelOrganic Chemistrybreast cancer ; prognosis ; interferon ; molecular subtypesbiochemical phenomena metabolism and nutritionGene signaturemedicine.diseaselcsh:Biology (General)lcsh:QD1-999bacteriaprognosisbusinessInternational Journal of Molecular Sciences
researchProduct

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

2011

Abstract Hydroxyurea is the standard therapy of chronic myelomonocytic leukemia (CMML) presenting with advanced myeloproliferative and/or myelodysplastic features. Response to hypomethylating agents has been reported in heterogeneous series of CMML. We conducted a phase 2 trial of decitabine (DAC) in 39 patients with advanced CMML defined according to a previous trial. Median number of DAC cycles was 10 (range, 1-24). Overall response rate was 38% with 4 complete responses (10%), 8 marrow responses (21%), and 3 stable diseases with hematologic improvement (8%). Eighteen patients (46%) demonstrated stable disease without hematologic improvement, and 6 (15%) progressed to acute leukemia. With…

OncologyNeuroblastoma RAS viral oncogene homologMalemedicine.medical_specialtyAntimetabolites AntineoplasticImmunologyDecitabineChronic myelomonocytic leukemiamedicine.disease_causeDecitabineBiochemistryhemic and lymphatic diseasesInternal medicinemedicineHumansSurvival analysisAgedAged 80 and overAcute leukemiaHematologybusiness.industryGene Expression Regulation LeukemicLeukemia Myelomonocytic ChronicCell BiologyHematologyMiddle Agedmedicine.diseasePrognosisSurvival AnalysisLeukemiaImmunologyMutationAzacitidineFemaleKRASbusinessmedicine.drugBlood
researchProduct

COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients?

2020

The world is facing a new pandemic caused by a novel beta coronavirus (COVID 19), which causes severe respiratory coronavirus syndrome (SARS-CoV-2). Unfortunately, there are currently no US Food and Drug Administration (FDA) approved medications for the treatment of COVID-19 patients. High mortality rates in frail patients is a notable feature of the virus registered since the onset of COVID-19 pandemic. Above all, elderly patients or those with underlying chronic illnesses and compromised immune system are most at risk (1). Thus, the consideration is that the possible coexistence, in the same individual, of a cancer diagnosis and a COVID-19 infection could generate a synergistic negative p…

OncologyOpinionmedicine.medical_specialty2019-20 coronavirus outbreakCancer ResearchtherapyCoronavirus disease 2019 (COVID-19)business.industrySettore MED/06 - Oncologia MedicaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)screeningCancerCOVID-19medicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282OncologyCOVID-19 cancer prognosis screening therapyInternal medicinemedicinecancerprognosisbusinessFrontiers in Oncology
researchProduct

Prognostic value of nuclear matrix protein expression in localized prostate cancer.

2012

The aim of the study was to correlate nuclear matrix (NM) protein expression profiles with the risk of PSA progression or death in early prostate cancer (PCa).High-resolution two-dimensional gel electrophoresis (2D-PAGE) was used to identify tumor-associated NM proteins in the PCa specimens obtained from 94 patients. The association between the expression of each protein and the probability of PSA progression or death was studied through univariate analysis. Unsupervised hierarchical clustering analysis was then used to generate patient clusters showing comparable outcomes by including the proteins that were predictive at univariate analysis. PSA-free and overall survival curves relative to…

OncologyPCA3MaleCancer Researchmedicine.medical_specialtyPrognosiPSA progressionValue (computer science)Kaplan-Meier EstimateNuclear matrix proteins; Prognosis Prostate cancer; PSA progressionurologic and male genital diseasesNuclear Matrix-Associated ProteinFollow-Up StudieProstate cancerNuclear Matrix-Associated ProteinsInternal medicinemedicineCluster AnalysisHumansElectrophoresis Gel Two-DimensionalNuclear matrix proteinMultivariate AnalysiProportional Hazards ModelsNuclear matrix proteinsHematologyCluster AnalysiProstate cancerProportional hazards modelbusiness.industryProstatic NeoplasmsPSA PROGRESSIONGeneral MedicineProstate-Specific AntigenNuclear matrixmedicine.diseasePrognosisProstate-specific antigenOncologyMultivariate AnalysisDisease ProgressionProportional Hazards ModelbusinessFollow-Up StudiesHuman
researchProduct

Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

2020

Contains fulltext : 218279.pdf (Publisher’s version ) (Open Access) Patients with acute myeloid leukemia (AML) harboring FLT3 internal tandem duplications (ITDs) have poor outcomes, in particular AML with a high (>/=0.5) mutant/wild-type allelic ratio (AR). The 2017 European LeukemiaNet (ELN) recommendations defined 4 distinct FLT3-ITD genotypes based on the ITD AR and the NPM1 mutational status. In this retrospective exploratory study, we investigated the prognostic and predictive impact of the NPM1/FLT3-ITD genotypes categorized according to the 2017 ELN risk groups in patients randomized within the RATIFY trial, which evaluated the addition of midostaurin to standard chemotherapy. The 4 …

OncologyPROBABILITIESMalePROGNOSISCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]NPM1 MUTATIONBiochemistryEuropean LeukemiaNetchemistry.chemical_compoundALLELIC RATIOAMLRisk FactorsGene Duplicationhemic and lymphatic diseasesMidostaurinFLT3Myeloid NeoplasiaHematopoietic Stem Cell TransplantationMyeloid leukemiaNuclear ProteinsHematologyCHEMOTHERAPYMiddle AgedPrognosisChemotherapy regimenEuropeLeukemia Myeloid Acutemedicine.anatomical_structureTreatment OutcomeTandem Repeat SequencesFemaleNucleophosminmedicine.medical_specialtyNPM1GenotypeImmunologyYOUNGER ADULTSInternal medicineWhite blood cellmedicineNORMAL CYTOGENETICSHumansGenetic Predisposition to DiseaseProportional Hazards ModelsProportional hazards modelbusiness.industryCell BiologyINTERNAL TANDEM DUPLICATIONTransplantationchemistryfms-Like Tyrosine Kinase 3Multivariate AnalysisbusinessSettore MED/15 - Malattie del Sangue
researchProduct

Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib

2021

Background Hepatocellular carcinoma (HCC) treatment remains a big challenge in the field of oncology. The liver disease (viral or not viral) underlying HCC turned out to be crucial in determining the biologic behavior of the tumor, including its response to treatment. The aim of this analysis was to investigate the role of the etiology of the underlying liver disease in survival outcomes. Patients and methods We conducted a multicenter retrospective study on a large cohort of patients treated with lenvatinib as first-line therapy for advanced HCC from both Eastern and Western institutions. Univariate and multivariate analyses were performed. Results Among the 1232 lenvatinib-treated HCC pat…

OncologyPhenylurea CompoundatezolizumabCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularQuinolinelenvatinibbevacizumabchemistry.chemical_compoundLiver diseaseRetrospective StudieNon-alcoholic Fatty Liver DiseaseInternal medicineMedicineHumansnonalcoholic steatohepatitisOriginal ResearchRetrospective StudiesUnivariate analysisSettore MED/12 - GastroenterologiaPerformance statusbusiness.industryPhenylurea CompoundsHazard ratioLiver NeoplasmsRetrospective cohort studyHepatitis Chepatocellular carcinomamedicine.diseasePrognosisdigestive system diseasesadvanced hepatocarcinoma; atezolizumab; bevacizumab; hepatitis C; hepatocellular carcinoma; immunotherapy; lenvatinib; nonalcoholic steatohepatitis; sorafenibadvanced hepatocarcinomaOncologychemistryLiver NeoplasmHepatocellular carcinomanonalcoholic steatohepatitiQuinolinessorafenibimmunotherapyhepatitis CbusinessLenvatinibHuman
researchProduct

Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma.

2019

In prostate adenocarcinoma (PCa), distinction between indolent and aggressive disease is challenging. Around 50% of PCa are characterized by TMPRSS2‐ERG (T2E)‐fusion oncoproteins defining two molecular subtypes (T2E‐positive/negative). However, current prognostic tests do not differ between both molecular subtypes, which might affect outcome prediction. To investigate gene‐signatures associated with metastasis in T2E‐positive and T2E‐negative PCa independently, we integrated tumor transcriptomes and clinicopathological data of two cohorts (total n = 783), and analyzed metastasis‐associated gene‐signatures regarding the T2E‐status. Here, we show that the prognostic value of biomarkers in PCa…

OncologyProstate adenocarcinomaMaleCancer Researchmedicine.medical_specialtyOncogene Proteins FusionKaplan-Meier EstimateAdenocarcinomaTMPRSS2MetastasisTranscriptome03 medical and health sciences0302 clinical medicineInternal medicinemedicineBiomarkers TumorHumansPrognostic biomarkerMetastasis ; Personalized Medicine ; Prognostic Biomarker ; Prostate Adenocarcinoma ; Tmprss2-ergNeoplasm MetastasisNeoplasm Stagingbusiness.industryGene Expression ProfilingComputational BiologyProstatic Neoplasmsmedicine.diseasePrognosisImmunohistochemistryGene Expression Regulation NeoplasticOncology030220 oncology & carcinogenesisImmunohistochemistryPersonalized medicineNeoplasm GradingbusinessErgInternational journal of cancerReferences
researchProduct